Literature DB >> 15103224

Immunohistochemical detection of estrogen receptor alpha in pituitary adenomas and its correlation with cellular replication.

Julia F S Pereira-Lima1, Caroline P Marroni, Cristina B Pizarro, Ligia M Barbosa-Coutinho, Nelson P Ferreira, Miriam C Oliveira.   

Abstract

With the aim of evaluating the relationship between pituitary tumorigenesis and the presence of estrogen receptor-alpha (ERalpha) by immunohistochemistry (IH) and their relevance to patients' clinical presentation, hormonal phenotypes of adenomas, preoperative neuroimaging findings, and the index of cellular replication MIB-1, a study was conducted with material from 91 women and 67 men with pituitary adenomas. The patients had acromegaly (29.7%), Cushing's disease (14.6%), hyperprolactinemic syndrome (20.9%), and clinically nonfunctioning tumors (34.8%). Of the patients, 14.6% had microadenomas, 52.5% had macroadenomas with or without suprasellar growth, 28.5% had invasive macroadenomas and in 4.4% the adenoma was not visualized. IH showed that 43 were positive for growth hormone (GH), 16 for corticotropin (ACTH), 18 for prolactin (PRL), 18 for PRL+GH, 6 for luteinizing hormone (LH) and follicle-stimulating hormone (FSH), 15 had a plurihormonal reaction, and 42 had nonfunctioning adenomas. The presence of ERalpha was positive in 9/158 adenomas with a median value for the percentage of labeled cells of 42.89%, and in 6/16 controls (autopsy samples) with a median value for the percentage of labeled cells of 0.024%. ERalpha was significantly more prevalent in controls than in patients with adenomas (37.5 versus 5.7%; p = 0.001); however, the mean ERalpha concentration in adenomas was significantly greater than in controls (42.89 versus 0.024%; p < 0.001). No significant difference in the concentration of ERalpha was found across the clinical presentations, hormonal phenotypes or findings of preoperative CT. Among the ERalpha-positive adenomas, ERalpha values were significantly greater in invasive macroadenomas (80%) than in microadenomas (3.33%). MIB-1 values did not differ significantly between ERalpha-positive and -negative adenomas, nor did the correlation between ERalpha values and the MIB-1 index attain significance in the total sample, even when only ERalpha-positive adenomas and positive MIB-1 indexes were considered. It was concluded that, when present in pituitary tumors, ERalpha exhibits a high concentration, and is more common in nonfunctioning and invasive adenomas, but absent in ACTH-secreting ones. Copyright 2004 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15103224     DOI: 10.1159/000077269

Source DB:  PubMed          Journal:  Neuroendocrinology        ISSN: 0028-3835            Impact factor:   4.914


  10 in total

1.  Expression patterns of ERα66 and its novel variant isoform ERα36 in lactotroph pituitary adenomas and associations with clinicopathological characteristics.

Authors:  Fatemeh Mahboobifard; Farahnaz Bidari-Zerehpoosh; Zahra Davoudi; Mahshid Panahi; Leila Dargahi; Mohammad H Pourgholami; Gieve Sharifi; Neda Izadi; Masoumeh Jorjani
Journal:  Pituitary       Date:  2020-06       Impact factor: 4.107

2.  Mice with inactivation of aryl hydrocarbon receptor-interacting protein (Aip) display complete penetrance of pituitary adenomas with aberrant ARNT expression.

Authors:  Anniina Raitila; Heli J Lehtonen; Johanna Arola; Elina Heliövaara; Manuel Ahlsten; Marianthi Georgitsi; Anu Jalanko; Anders Paetau; Lauri A Aaltonen; Auli Karhu
Journal:  Am J Pathol       Date:  2010-08-13       Impact factor: 4.307

Review 3.  Familial isolated pituitary adenomas (FIPA) and the pituitary adenoma predisposition due to mutations in the aryl hydrocarbon receptor interacting protein (AIP) gene.

Authors:  Albert Beckers; Lauri A Aaltonen; Adrian F Daly; Auli Karhu
Journal:  Endocr Rev       Date:  2013-01-31       Impact factor: 19.871

4.  Expression of D2RmRNA isoforms and ERmRNA isoforms in prolactinomas: correlation with the response to bromocriptine and with tumor biological behavior.

Authors:  Zhe Bao Wu; Wei Ming Zheng; Zhi Peng Su; Yong Chen; Jin Sen Wu; Cheng De Wang; Chen Lin; Yan Jun Zeng; Qi Chuan Zhuge
Journal:  J Neurooncol       Date:  2010-01-09       Impact factor: 4.130

5.  Aromatase enzyme expression in acromegaly and its possible relationship with disease prognosis.

Authors:  Alev Selek; Berrin Cetinarslan; Yesim Gurbuz; Ilhan Tarkun; Zeynep Canturk; Burak Cabuk
Journal:  Endocrine       Date:  2014-10-10       Impact factor: 3.633

6.  Is there any gender difference in epidemiology, clinical presentation and co-morbidities of non-functioning pituitary adenomas? A prospective survey of a National Referral Center and review of the literature.

Authors:  C Di Somma; E Scarano; G de Alteriis; L Barrea; E Riccio; R Arianna; S Savastano; A Colao
Journal:  J Endocrinol Invest       Date:  2020-09-07       Impact factor: 4.256

Review 7.  Molecular Network Basis of Invasive Pituitary Adenoma: A Review.

Authors:  Qi Yang; Xuejun Li
Journal:  Front Endocrinol (Lausanne)       Date:  2019-01-24       Impact factor: 5.555

8.  FSH Levels Are Related to E-cadherin Expression and Subcellular Location in Nonfunctioning Pituitary Tumors.

Authors:  Anders J Kolnes; Kristin A B Øystese; Nicoleta C Olarescu; Geir Ringstad; Jon Berg-Johnsen; Olivera Casar-Borota; Jens Bollerslev; Anders P Jørgensen
Journal:  J Clin Endocrinol Metab       Date:  2020-08-01       Impact factor: 5.958

9.  Sexual Dimorphism in Cellular and Molecular Features in Human ACTH-Secreting Pituitary Adenomas.

Authors:  Francesca Pecori Giraldi; Maria Francesca Cassarino; Antonella Sesta; Mariarosa Terreni; Giovanni Lasio; Marco Losa
Journal:  Cancers (Basel)       Date:  2020-03-13       Impact factor: 6.639

10.  Metformin inhibits growth and prolactin secretion of pituitary prolactinoma cells and xenografts.

Authors:  Jun Gao; Yang Liu; Gaijing Han; Kan Deng; Xiaohai Liu; Xinjie Bao; Ming Feng; Yong Yao; Wei Lian; Bing Xing; Xiang Lv; Renzhi Wang
Journal:  J Cell Mol Med       Date:  2018-10-18       Impact factor: 5.310

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.